KAI to report Phase II data in hyperparathyroidism in end-stage renal disease this year
This article was originally published in Scrip
Executive Summary
KAI Pharmaceuticals expects to report Phase II results for its second clinical phase drug candidate, KAI-4169, for the treatment of secondary hyperparathyroidism (SHPT) in end-stage renal disease patients, in the second half of 2011.